# SANGAMO THERAPEUTICS, INC (SGMO) — bankruptcy/chapter_11 [announced]
Source: SEC API (secapi.ai) · situation sit_9096d8ea6832cf9280be · retrieved 2026-08-11T15:54:05.724Z

## Overview
Sangamo Therapeutics develops gene-editing and cell therapy treatments using its proprietary zinc finger protein technology platform.

Sangamo Therapeutics, Inc., a gene-editing and cell therapy company, filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. On July 14, 2026, the Court entered the Bidding Procedures Order approving auction and bidding procedures for the sale of all or substantially all of the Company's assets. Key dates include: bid deadline of August 4, 2026 at 5:00 p.m. (Eastern Time); auction on August 10, 2026 at 10:00 a.m. (Eastern Time) if multiple qualified bids are received; and Sale Hearing on August 20, 2026 at 10:00 a.m. (Eastern Time) for Court approval of successful bids. The Company continues to operate as a debtor-in-possession and seeks to maximize value for stakeholders through asset sales or reorganization.

## Key dates
- Announced 2026-07-20 · Expiry 2026-08-04

## Timeline
- 2026-07-20 · 8-K (0001193125-26-309012): 8-K - SANGAMO THERAPEUTICS, INC — *Sangamo Therapeutics develops gene-editing and cell therapy treatments using its proprietary zinc finger protein technology platform.* Sangamo Therapeutics, Inc., a gene-editing and cell therapy company, filed a voluntary Chapter 11 bankruptcy petition on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. On July 14, 2026, the Court entered the Bidding Procedures Order approving auction and bidding procedures for the sale of all or substantially all of the Company's assets. Key dates include: bid deadline of August 4, 2026 at 5:00 p.m. (Eastern Time); auction on August 10, 2026 at 10:00 a.m. (Eastern Time) if multiple qualified bids are received; and Sale Hearing on August 20, 2026 at 10:00 a.m. (Eastern Time) for Court approval of successful bids. The Company continues to operate as a debtor-in-possession and seeks to maximize value for stakeholders through asset sales or reorganization.
  https://www.sec.gov/Archives/edgar/data/1001233/0001193125-26-309012.txt

## Citations
- 0001193125-26-309012 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526309012